Amrubicin for the treatment of neuroendocrine carcinoma of the gastrointestinal tract: A retrospective analysis of five cases

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 5, 2011, Pages 1325-1330

  Asayama, Masako ^a   Fuse, Nozomu ^a   Yoshino, Takayuki ^a   Yano, Tomonori ^a   Tahara, Makoto ^a   Doi, Toshihiko ^a   Fujii, Satoshi ^a   Ohtsu, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

Amrubicin; Chemotherapy; Gastrointestinal tract; Neuroendocrine carcinoma; Small cell carcinoma

Indexed keywords

AFLIBERCEPT; AMRUBICIN; CETUXIMAB; CISPLATIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; OXALIPLATIN; UFT;

ADULT; AGED; ANEMIA; ANOREXIA; ANUS CARCINOMA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CARCINOMA; CLINICAL ARTICLE; COLON CARCINOMA; COLON TUMOR; CONSTIPATION; DIARRHEA; DRUG DOSE REDUCTION; DRUG RESPONSE; DRUG TREATMENT FAILURE; ESOPHAGUS CARCINOMA; ESOPHAGUS TUMOR; FEBRILE NEUTROPENIA; FEMALE; FEVER; GASTROINTESTINAL TRACT NEUROENDOCRINE CARCINOMA; HEMATOLOGIC DISEASE; HISTOLOGY; HUMAN; LEUKOPENIA; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SALVAGE THERAPY; SURVIVAL TIME; THROMBOCYTHEMIA; TUMOR LOCALIZATION; TUMOR REGRESSION;

AGED; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 82455212067     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1619-7     Document Type: Article

References (28)

1. CG Moertel LK Kvols MJ O'Connell J Rubin 1991 Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin Cancer 68 227 232 1712661 10.1002/1097-0142(19910715)68:2<227::AID-CNCR2820680202>3.0.CO;2-I 1:STN:280:DyaK3MzgtVCjuw%3D%3D
2. E Mitry E Baudin M Ducreux, et al. 1999 Treatment of poorly differentiated neuroendocrine tumors with etoposide and cisplatin Br J Cancer 81 1351 1355 10604732 10.1038/sj.bjc.6690325 1:CAS:528:DC%2BD3cXls1KksA%3D%3D
3. Machida N, Boku N, Onozawa Y et al (2009) Treatment of metastatic poorly differentiated neuroendocrine carcinoma (PDNEC) with irinotecan plus cisplatin. Eur J Cancer Supple 7: 397 (ECCO15-34th ESMO Multidisciplinary Congress, Abstr. P-6624)
4. J Hainsworth DR Spigel S Litchy A Greco 2006 Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study J Clin Oncol 24 3548 3554 16877720 10.1200/JCO.2005.05.0575 1:CAS:528: DC%2BD28XovVSjs7w%3D (Pubitemid 46630525)
5. Hou Z, Elasmar SA, Lozano R et al (2003) A pilot study of irinotecan plus cisplatin in patients with metastatic high-grade neuroendocrine carcinoma. Proc Am Soc Clin Oncol 22 (Abstr. 1508)
6. DM Maru H Khurana A Rashid AM Correa S Anandasabapathy S Krishnan, et al. 2008 Retrospective study of clinicopathologic features and prognosis of high-grade neuroendocrine carcinoma of the esophagus Am J Surg Pathol 32 1404 1411 18670347 10.1097/PAS.0b013e31816bf41f
7. R Chetty 2008 An overview of practical issues in the diagnosis of gastroenteropancreatic neuroendocrine pathology Arch Pathol Lab Med 132 1285 1289 18684027
8. Tsuda N, Kato K, Takahari D et al (2007) Neuroendocrine tumor (NET) of the stomach: Institutional experience and efficacy of irinotecan (CPT-11) plus cisplatin (CDDP). J Clin Oncol: abstr. 82 (2007 Gastrointestinal Cancer Symposium-ASCO)
9. K Chin S Baba H Hosaka, et al. 2008 Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: report of 12 cases from single institution experience Jpn J Clin Oncol 38 426 431 18519543 10.1093/jjco/hyn041 (Pubitemid 351965947)
10. K Arai M Matsuda 1998 Gastric small-cell carcinoma in Japan: a case report and review of the literature Am J Clin Oncol 21 458 461 9781599 10.1097/00000421-199810000-00007 1:STN:280:DyaK1cvlt1ymuw%3D%3D (Pubitemid 28480495)
11. K Matsui M Kitagawa A Miwa Y Kuroda M Tsuji 1991 Small cell carcinoma of the stomach: a clinicopathologic study of 17 cases Am J Gastroenterol 86 1167 1175 1715667 1:STN:280:DyaK3MzltlGjuw%3D%3D
12. Bosman FT, Carbeuri F, Hruban RH, Theise ND (2010) WHO classification of tumors of the digestive system, 4th edn. WHO Press, Geneva, pp 13-14
13. B Brenner LH Tang J Shia DS Klimstra DP Kelsen 2007 Small cell carcinoma of the gastrointestinal tract: clinicopathological features and treatment approach Semin Oncol 34 43 50 17270665 10.1053/j.seminoncol.2006.10.022 1:CAS:528:DC%2BD2sXjtFCgsLc%3D (Pubitemid 46172492)
14. Ministry of Education, Culture, Sports, Science and Technology, Ministry of Health, Labour and Welfare (2002) Ethical guidelines for epidemiologic research. http://www.niph.go.jp/wadai/ekigakurinri/rinrishishin.htm. Accessed 26 Jan 2011
15. BJ Roth DH Johnson LH Einhorm LP Schacter NC Cherng HJ Cohen J Crawford JA Randolph JL Goodlow GO Broun, et al. 1992 Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alteration of these two regimens in extensive small-cell lung cnacer: a phase III trial of the Southeastern Cancer Study Group J Clin Oncol 10 282 291 1310103 1:STN:280:DyaK387itF2nsg%3D%3D
16. K Noda Y Nishiwaki M Kawahara, et al. 2002 Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer N Engl J Med 346 85 91 11784874 10.1056/NEJMoa003034 1:CAS:528: DC%2BD38Xkt1OlsA%3D%3D (Pubitemid 34438898)
17. J von Pawel JH Schiller FA Shephered, et al. 1999 Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer J Clin Oncol 17 658 667 (Pubitemid 29075255)
18. A Inoue S Sugawara K Yamazaki, et al. 2008 Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402 J Clin Oncol 26 5401 5406 18854562 10.1200/JCO.2008.18.1974 1:CAS:528: DC%2BD1MXhslCmuw%3D%3D
19. Kato T, Nokihara H, OheY et al (2006) Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC). J Clin Oncol. ASCO Annual Meeting Proceedings Part I; 24(18S):7061
20. S Onoda N Masuda T Seto, et al. 2006 Phase II trial of amrubicin treatment of refractory or relapsed small-cell lung cancer: Thoracic Oncology Research Group Study 0301 J Clin Oncol 24 5448 5453 17135647 10.1200/JCO.2006.08.4145 1:CAS:528:DC%2BD2sXisVSitQ%3D%3D (Pubitemid 46623179)
21. DS Ettinger R Jotte P Lorigan, et al. 2010 Phase II study of amrubicin as second-line therapy in patients with platinum-refractory small-cell lung cancer J Clin Oncol 28 2598 2603 20385980 10.1200/JCO.2009.26.7682
22. MM Gottesman T Fojo SE Bates 2002 Multidrug resistance in cancer: role of ATP-dependent transporters Nat Rev Cancer 2 48 58 11902585 10.1038/nrc706 1:CAS:528:DC%2BD38XhvF2jtL8%3D (Pubitemid 37328807)
23. T Yamaoka M Hanada S Ichii, et al. 1999 Uptake and intracellular distribution of amrubicin, a novel 9-amino-anthracycline and its active metabolite amrubicinol in P388 murine leukemia cells Jpn J Cancer Res 90 685 690 10429662 10.1111/j.1349-7006.1999.tb00801.x 1:CAS:528:DyaK1MXktFOhtbY%3D (Pubitemid 29332929)
24. A Hira H Watanabe Y Maeda, et al. 2008 Role of P-glycoprotein in accumulation and cytotoxicity of amrubicin and amrubicinol in MDR1 gene-transfected LLC-PK1 cells and human A549 lung adenocarcinoma cells Biochem Pharm 75 973 980 18054347 10.1016/j.bcp.2007.10.023 1:CAS:528: DC%2BD1cXhsFymurg%3D (Pubitemid 351174119)
25. M Katou N Soga T Onishi K Arima Y Sugimura 2008 Small cell carcinoma of the prostate treated with amrubicin Int J Clin Oncol 13 169 172 18463964 10.1007/s10147-007-0702-x (Pubitemid 351668165)
26. Isobe T, Yanai S, Kusaba H, Yada S, Kuroda Y, Tamiya S et al (2009) Effective monotherapy with amrubicin for a refractory extrapulmonary small-cell carcinoma of the liver. Case Reports in Medicine Article ID 538081
27. S Igawa H Murayama N Yamamoto 2009 Thymic small cell carcinoma shows marked response to amrubicin J Thorac Oncol 4 778 779 19461410 10.1097/JTO.0b013e3181a52e74
28. Jotte RM, Conkling PR, Reynolds C, Allen AR, Oliver JW (2008) A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive disease small-cell lung cancer (SCLC) sensitive to platinum-based first line chemotherapy. J Clin Oncol 26 (May 20 suppl; abstr 8040)